Importer of Controlled Substances Notice of Application, 35020-35021 [2012-14161]
Download as PDF
35020
Federal Register / Vol. 77, No. 113 / Tuesday, June 12, 2012 / Notices
depressant,46 was a controlled
substance. (Tr. 178–79 (‘‘He asked me
what a controlled substance was, and
whether Xanax was a controlled
substance.’’).) Respondent testified that
he commonly prescribes Xanax.
(Tr. 778–79.)
There is additional record evidence
reflecting Respondent’s attitude toward
diversion and his course of compliance
with Arizona medical standards but
further elaboration is unnecessary. As to
all of these incidents, Respondent’s
testimony at hearing that his motivation
‘‘was first and foremost the well-being
of my patients,’’ (Tr. 757), is availing, to
a point. But Respondent’s prepared
testimony at hearing does not counter
the more substantial weight properly
given to his candid, un-coached remarks
and behaviors toward undercover
investigators posing as patients. These
remarks and behaviors are telling, and I
find substantial evidence that
Respondent will engage in future
misconduct if allowed to maintain his
registration. In sum, Factor Five weighs
in favor of a finding that Respondent’s
continued registration would be
inconsistent with the public interest.
srobinson on DSK4SPTVN1PROD with NOTICES
IV. Conclusion and Recommendation
I find that a balancing of the foregoing
public interest factors supports a finding
that the Government has established a
prima facie case in support of
revocation of Respondent’s registration,
or denial of an application for
registration.47 I conclude by a
preponderance of the evidence that the
Government has proved independent
grounds for revoking Respondent’s COR
pursuant to 21 U.S.C. § 824(a)(1), and
alternatively, that the balance of the
other factors in this case weighs heavily
in favor of a finding that Respondent’s
registration would be inconsistent with
the public interest under 21 U.S.C.
§ 823(f).
Once DEA has made its prima facie
case for revocation, the burden then
shifts to the respondent to show that,
46 Alprazolam is a controlled substance. 21 C.F.R.
§ 1308.14(c) (2010). I take official notice that Xanax
is a trade name for alprazolam. Respondent can
dispute the facts of which I take official notice by
filing a properly supported motion for
reconsideration within twenty days of service of
this Recommended Decision, which shall begin on
the date it is mailed. See supra note 40. See
generally Joseph Gaudio, M.D., 74 Fed. Reg. 10,083,
10,088 (DEA 2009).
47 Respondent all but concedes as much, arguing
that ‘‘Respondent is well aware that the Presiding
Administrative Law Judge is likely to determine
that the government has made a prima facie case
against him. That having been acknowledged, the
record supports by a preponderance of the evidence
a finding that his continued registration is not
inconsistent with the public interest.’’ (Resp’t Br.
31.)
VerDate Mar<15>2010
22:42 Jun 11, 2012
Jkt 226001
given the totality of the facts and
circumstances in the record, revoking
the registrant’s registration would not be
appropriate. Morall v. DEA, 412 F.3d
165, 174 (D.C. Cir. 2005); Humphreys v.
DEA, 96 F.3d 658, 661 (3d Cir. 1996);
Shatz v. United States Dep’t of Justice,
873 F.2d 1089, 1091 (8th Cir. 1989);
Thomas E. Johnston, 45 Fed. Reg.
72,311, 72,311 (DEA 1980).
Additionally, where a registrant has
committed acts inconsistent with the
public interest, the registrant must
accept responsibility for his or her
actions and demonstrate that he or she
will not engage in future misconduct.
Patrick W. Stodola, 74 Fed. Reg. 20,727,
20,735 (DEA 2009). Also,
‘‘[c]onsideration of the deterrent effect
of a potential sanction is supported by
the CSA’s purpose of protecting the
public interest.’’ Joseph Gaudio, M.D.,
74 Fed. Reg. 10,083, 10,094 (DEA 2009).
An agency’s choice of sanction will be
upheld unless unwarranted in law or
without justification in fact. A sanction
must be rationally related to the
evidence of record and proportionate to
the error committed. See Morall v. DEA,
412 F.3d 165, 181 (D.C. Cir. 2005)
(sanction will be upheld unless
unwarranted in law or without
justification in fact). Finally, an ‘‘agency
rationally may conclude that past
performance is the best predictor of
future performance.’’ Alra Laboratories,
Inc. v. DEA, 54 F.3d 450, 452 (7th Cir.
1995).
The evidence as a whole demonstrates
that Respondent has not credibly
accepted responsibility for his actions,
or presented evidence that could
reasonably support a finding that he
will not engage in future misconduct.
Accordingly, Respondent has failed to
rebut the Government’s prima facie
case. I therefore recommend that
Respondent’s DEA COR be revoked and
any pending applications for renewal
denied.
Dated: January 20, 2011
Timothy D. Wing
Administrative Law Judge
[FR Doc. 2012–14268 Filed 6–11–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on October
6, 2011, Arizona Department of
Corrections, ASPC–Florence, 1305 E.
Butte Avenue Florence, Arizona 85132,
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Pentobarbital (2270), a basic class of
controlled substance listed in schedule
II.
The facility intends to import the
above listed controlled substance for
legitimate use. Supplies of this
particular controlled substance are
inadequate and are not available in the
form needed within the current
domestic supply of the United States.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive
Springfield, Virginia 22152; and must be
filed no later than [insert date 30 days
from date of publication].
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
E:\FR\FM\12JNN1.SGM
12JNN1
Federal Register / Vol. 77, No. 113 / Tuesday, June 12, 2012 / Notices
Dated: June 4, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–14161 Filed 6–11–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 11–44]
Kwan Bo Jin, M.D.; Decision and Order
srobinson on DSK4SPTVN1PROD with NOTICES
On October 13, 2011, an agency
Administrative Law Judge issued the
attached recommended decision.
Neither party filed exceptions to the
decision.
Having reviewed the entire record, I
have decided to adopt the ALJ’s findings
of fact and conclusions of law, except
for his discussion of the role of
community impact evidence in agency
proceedings, see ALJ, at 14–16; 1 which
is contrary to agency precedent.2 See
1 All citations to the ALJ’s Recommended
Decision are to the slip opinion as originally issued.
2 I also do not adopt the ALJ’s statement at page
7 of the slip opinion stating his conclusion ‘‘that the
reference in Section 823(f)(5) to ‘other conduct
which may threaten the public health and safety’
would as a matter of statutory interpretation
logically encompass the factors listed in Section
824(a).’’ ALJ at 7 (citing Kuen H. Chen, M.D., 58 FR
65401, 65402 (1993)).
To be sure, the Agency decision in Chen stated
that ‘‘[t]he administrative law judge has concluded
here that the reference in 21 U.S.C. 823(f)(5) to
‘other conduct which may threaten the public
health and safety’ would as a matter of statutory
interpretation logically encompass the bases listed
in 21 U.S.C. 824(a).’’ 58 FR at 65402. However,
whether this constitutes a holding or merely
dictum, Chen is totally devoid of any indication
that the traditional tools of statutory construction
(i.e, text, structure, statutory purpose, and
legislative history) were employed in reaching this
conclusion. Indeed, while factor five focuses on
‘‘other conduct,’’ several of the grounds for
revocation are based on a registrant’s status and do
not require inquiry into the nature of the underlying
conduct. See 21 U.S.C. 824(a)(3) (authorizing
revocation where registrant ‘‘has had his State
license or registration suspended, revoked, or
denied by competent State authority and is no
longer authorized’’ to engage in controlled
substance activities or such sanction has been
recommended by competent state authority); id.
824(a)(5) (authorizing revocation where registrant
has been excluded or is subject to exclusion from
participating in federal healthcare programs under
mandatory exclusion provisions). In addition,
construing factor five in this manner renders
superfluous factor one, which authorizes the
Agency to consider the recommendation of the state
licensing board or disciplinary authority, as well as
the provision of section 823(f) stating that the ‘‘[t]he
Attorney General shall register practitioners . . . if
the applicant is authorized to dispense . . .
controlled substances under the laws of the State
in which he practices.’’
Finally, it should be noted that since shortly after
the CSA’s enactment and years before section 823(f)
was amended to include the public interest factors,
VerDate Mar<15>2010
22:42 Jun 11, 2012
Jkt 226001
Linda Sue Cheek, 76 FR 66972, 66973
(2011); Mark De La Lama, 76 FR 20011,
20020 n.20 (2011); Bienvenido Tan, 76
FR 17673, 17694 n.58 (2011); Gregory D.
Owens, 74 FR 36571, 36757 & n.22
(2009). Nonetheless, my rejection of the
ALJ’s discussion of this issue has no
effect on the outcome of this matter.
Here, the sole ground for revocation
proven on this record was Respondent’s
having been mandatorily excluded from
participating in federal health care
programs pursuant to 42 U.S.C. 1320a–
7(a). Respondent, however, has credibly
accepted responsibility for the
misconduct which led to his conviction
for health care fraud, see 18 U.S.C. 1347,
complied with the terms of his sentence,
and also demonstrated that he has
undertaken remedial measures.
Accordingly, I have decided to adopt
the ALJ’s conclusion that his continued
registration would be ‘‘consistent with
the public interest.’’ ALJ at 20.
Therefore, the Order to Show Cause will
be dismissed.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 824(a), as well as 28 CFR
0.100(b), I order that the Order to Show
Cause issued to Kwan Bo Jin, M.D., be,
and it hereby is, dismissed. This Order
is effective immediately.
Dated: June 4, 2012.
Michele M. Leonhart,
Administrator.
D. Linden Barber, Esq., and Jonathan P.
Novak, Esq., for the Government
DEA ‘‘has consistently held that where a
registration can be revoked under section 824, it
can, a fortiori, be denied under section 823 since
the law would not require an agency to indulge in
the useless act of granting a license on one day only
to withdraw it on the next.’’ Serling Drug Co. v.
Detroit Prescription Wholesaler, Inc., 40 FR 11918,
11919 (1975). See also John R. Amato, 40 FR 22852
(1975) (Denying application where practitioner’s
state license had been revoked, holding that section
823(f) ‘‘must logically give the Administrator the
authority to deny a registration if the practitioner
is not authorized by the State to dispense controlled
substances . . . . To hold otherwise would mean
that all applications would have to be granted only
to be revoked the next day under 21 U.S.C.
824(a)(3). This [A]gency has consistently held that
where a registration can be revoked under section
824, it can, a fortiori, be denied under section
823.’’).
Indeed, no court has ever questioned the
Agency’s longstanding and consistent interpretation
that it has authority to deny an application on any
of the grounds set forth in section 824(a). Cf.
National Muffler Dealers Assn., Inc., v. United
States, 440 U.S. 472, 477 (2011) (‘‘A regulation may
have particular force if it is a substantially
contemporaneous construction of the statute by
those presumed to have been aware of
congressional intent.’’); EEOC v. Associated Dry
Goods Corp., 449 U.S. 590, 600 n.17 (1981) (‘‘a
contemporaneous construction deserves special
deference when it has remained consistent over a
long period of time’’).
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
35021
Glen D. Crick, Esq., and Lillian
Walanka, Esq., for the Respondent.
Recommended Ruling, Findings of Fact,
Conclusions of Law and Decision of the
Administrative Law Judge
Introduction
This proceeding is an adjudication
pursuant to the Administrative
Procedure Act, 5 U.S.C. 551 et seq., to
determine whether the Drug
Enforcement Administration (‘‘DEA’’ or
‘‘Government’’) should revoke a
practitioner’s Certificate of Registration
(‘‘COR’’), and deny any pending
applications for renewal or
modification. Without this registration,
the practitioner, Kwan Bo Jin, M.D.
(‘‘Respondent’’), of Palatine, Illinois,
would be unable to lawfully possess,
prescribe, dispense or otherwise handle
controlled substances in the course of
his practice.
On March 29, 2011, the Deputy
Assistant Administrator, Office of
Diversion Control, DEA, issued an Order
to Show Cause (‘‘OSC’’) to Respondent,
giving Respondent notice of an
opportunity to show cause why the DEA
should not revoke Respondent’s DEA
COR BJ1801580, pursuant to 21 U.S.C.
823 and 824, and deny Respondent’s
pending application as a practitioner for
registration in Schedules II through V,
alleging that Respondent has been
excluded from participation in all
federal health care programs as defined
in 21 U.S.C. 824(a)(5). (ALJ Ex. 1, at 1.)
The OSC alleged in substance: (a)
Respondent is currently registered with
DEA as a practitioner in Schedules II
through V under DEA registration
number BJ1801580, at 950 West Carolyn
Drive, Palatine, Illinois; (b)
Respondent’s registration expired on
December 31, 2009, and Respondent
‘‘submitted a timely renewal on
November 6, 2010;’’ 1 (c) the United
States Department of Health and Human
Services (‘‘HHS’’) by letter dated April
30, 2010, notified Respondent of his
exclusion from participation in all
federal health programs based on his
October 21, 2009 federal conviction for
health care fraud pursuant to 18 U.S.C.
1347; and (d) the exclusion was
effective on May 20, 2010, and remains
in place until at least May 19, 2015.2
(Id.)
Respondent, through counsel, timely
requested a hearing, (ALJ Ex. 2), which
1 Upon inquiry at hearing, the Government
indicated that the date in the OSC was in error and
should reflect November 6, 2009.
2 At hearing, the Government raised an additional
issue involving Respondent’s prescribing of the
Schedule II controlled substance Ritalin to a patient
over a two to three month time period in or about
1996.
E:\FR\FM\12JNN1.SGM
12JNN1
Agencies
[Federal Register Volume 77, Number 113 (Tuesday, June 12, 2012)]
[Notices]
[Pages 35020-35021]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-14161]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on October 6, 2011, Arizona Department of Corrections, ASPC-
Florence, 1305 E. Butte Avenue Florence, Arizona 85132, made
application to the Drug Enforcement Administration (DEA) to be
registered as an importer of Pentobarbital (2270), a basic class of
controlled substance listed in schedule II.
The facility intends to import the above listed controlled
substance for legitimate use. Supplies of this particular controlled
substance are inadequate and are not available in the form needed
within the current domestic supply of the United States.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration, and may, at the same time, file a written
request for a hearing on such application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive Springfield, Virginia 22152; and must be filed no
later than [insert date 30 days from date of publication].
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
[[Page 35021]]
Dated: June 4, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-14161 Filed 6-11-12; 8:45 am]
BILLING CODE 4410-09-P